Immuneering Corp. (IMRX), Tuesday announced positive data update from three arms of its ongoing Phase 2a trial of lead program IMM-1-104 for the treatment of patients with Pancreatic cancer.
Following the announcement, Immuneering's stock is surging 103.39 percent, to $4.83 on the Nasdaq.
The drug showed an overall response rate of 43 percent and disease control rate of 86 percent in first-line Pancreatic cancer patients, when combined with modified gemcitabine/nab-paclitaxel. Whereas, the combination with modified Folfirinox demonstrated target lesion shrinkage in all evaluable patients, including a 100 percent reduction.
Meanwhile, the initial data for IMM-1-104 monotherapy in second-line pancreatic cancer revealed a partial response of 67 percent target lesion reduction, demonstrated activity and supported development in first-line combinations.
The biotechnology company intends to add three new Phase 2a combination arms - IMM-1-104 with a BRAF inhibitor in BRAF-mutant melanoma, and IMM-1-104 with an immune checkpoint inhibitor in both melanoma and non-small cell lung cancer, set to begin in 2025.
For comments and feedback contact: editorial@rttnews.com
Health News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.